We are a revolutionary biotherapeutics company and our mission is to revolutionize autoimmune and allergic disease treatment by resetting the immune system for superior disease remission.

How?

By resetting the immune system using novel macrophage and monocyte biology. Our first-in-class targets modify the immune cascade upstream at its source, and impact both the regulatory and effector arms of the immune system. On the regulatory side, they upregulate T and B regulatory cells. On the effector side, they downregulate CD4+ and CD8+ T cells. This upstream approach results in a prolonged effect that could potentially lead to superior disease remission for patients without chronic exposure to therapy or broad immune suppression.

Why?

Existing therapies for autoimmune and allergic diseases require frequent chronic dosing, provide only short-term disease remission in a limited number of patients and suppress the immune system, ultimately putting patients at risk of developing serious infections and life-threatening side effects.